Research

Title Filter

Display #

#	Article Title	Author	Hits
1	Adeona's reaZin, A Better Preventative than Cure?	Chemistfrog	580
2	FDA Panel Votes in Favor of Orexigen's Contrave (OREX)	TapeBeat Staff	1154
3	Biodel's Stock Plunges Heavy as Company Receives CRL for Linjeta (BIOD)	TapeBeat Staff	1338
4	Clarity on Linjeta from FDA May Give Shares a Boost (BIOD)	TapeBeat Staff	2649
5	Results of Synergistic Collaboration of Merck/Ariad Pharma Nearing (ARIA, MRK)	Stephen Ramey	1542
6	Earnings Season Unofficially Kicks off with a Bang, Alcoa Inc (NYSE: AA)	TB Staff	822
7	Micron Technology Earnings Fall Short of Consensus Estimates (NASDAQ: MU)	TapeBeat Staff	709
8	Sanofi-Aventis's Prowl for New Insulin, Could it be Biodel's Linjeta? (BIOD, SNY)	Joseph Krueger	4269
9	Linjeta Study Results expected to be Presented Between Sept 20-23, Biodel Inc (NASDAQ: BIOD)	TapeBeat Staff	1463
10	FDA Advisory Panel Votes Against Arena Pharmaceuticals, Inc's Drug (NASDAQ: ARNA)	Tapebeat Staff	1157
11	Wedbush Rates an Outperform on Cadence Pharmaceuticals (NASDAQ: CADX)	V Nukala	1161
12	Manufacturer Responds to FDA's Warning Letter, Biodel Inc (NASDAQ: BIOD)	TapeBeat Staff	1658
13	The Q2 Financial's of Jazz Pharma May Impact the Share Price Closer to FDA Panel (NASDAQ: JAZZ)	Mark Messier	711
14	Getting Closer to Priority Review PDUFA Date for Acetadote (NASDAQ: CPIX)	Mark Messier	1221
15	Investors All Worried About Qnexa FDA Panel Review This Week (ARNA, OREX, VVUS)	Joseph Krueger	2136
16	CytoSorb Filter is a Novel Application of an Older Technology (OTC:CTSO)	Stephen Ramey	1634
17	Fans of Fanapt Are On To Something (NASDAQ:VNDA)	Joseph Krueger	3721
18	NMT Medical Seems to be Dramatically Oversold after CLOSURE Trial Data (NASDAQ:NMTI)	Stephen Ramey	862
19	Shopping the Biotech Clearance Rack at 50% off (CLDX, BIOD, MNKD, POZN)	Joseph Krueger	1976
20	Javelin Pharmaceuticals Risk versus Reward (JAV, HSP)	Venkat Nukala	1180

Page 1 of 2

«
Start
Prev
1
2
Next
End
»


Receive TextHTML	Terms and Conditions